Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Acute myeloid leukemia in the elderly has a poor prognosis using standard therapy. Lenalidomide is a thalidomide analogue with activity at low doses for low-risk MDS harboring a 5q-. Two institutions using different protocols evaluated high-dose lenalidomide induction (35-50 mg daily for 14-21 days, 14-30 days of rest) followed by lower dose maintenance (10 mg daily). Out of 33 patients, four patients had a complete response.

Molecular Tests Discriminate Prognosis in Normal Karyotype AML